Riskpilot← Back to searchSign inGet full accessNORDICDX AS
ASActiveOrg 925141933Richard Johnsens Gate 4, 4021 StavangerWholesale of pharmaceutical and medical goods · NACE 4646Est. 20208 employees
Revenue 2024
NOK 1,8M
+119% vs 2023
EBITDA margin
20.6%
+128% vs 2023
Equity ratio
22.4%
Financial strength
Net profit 2024
NOK 446K
+131% vs 2023
| Revenue | NOK 1,8M | +119% |
| EBITDA | NOK 367K | +128% |
| Net profit | NOK 446K | +131% |
| Total assets | NOK 6,6M | +529% |
| Equity | NOK 1,5M | +4547% |
| Employees | 8 | — |
Legal name
NORDICDX AS
Org number
925141933
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. juni 2020
Share capital
NOK 114 600
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Kjøp og salg av utstyr samt tilby tjenester for diagnostikk av mennesker og landbruk. Selskapet kan også eie aksjer og andeler i andre selskap.
Address
Richard Johnsens Gate 4, 4021 Stavanger
Phone
+4790093118
Email
post@nordicdx.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 11 141 | 2 675 | 813 | 1 779 |
| Staff expenses | −0 | −570 | −1 560 | −791 | −787 |
| EBITDA | −28 | 5 282 | −704 | −1 305 | 367 |
| Depreciation & amort. | −0 | −92 | −23 | −130 | −151 |
| EBIT | −28 | 5 190 | −727 | −1 435 | 216 |
| Net financials | −7 | −12 | 8 | −15 | −237 |
| Profit before tax | −35 | 5 178 | −719 | −1 450 | −21 |
| Tax | −10 | 1 143 | −0 | −0 | −467 |
| Net profit | −25 | 4 035 | −719 | −1 450 | 446 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 167 | 6 918 | 3 119 | 1 048 | 6 591 |
| Equity | 165 | 4 201 | 1 481 | 32 | 1 477 |
| Long-term debt | 0 | 0 | 0 | 653 | 4 383 |
| Short-term debt | 2 | 2 718 | 1 637 | 363 | 730 |
| Total debt | 2 | 2 718 | 1 637 | 1 016 | 5 113 |
EBITDA margin
20.6%
This company
15.8%
Market median
+30% vs market
20202024
Equity ratio
22.4%
This company
38.2%
Market median
-41% vs market
20202024
Return on equity
30.2%
This company
18.4%
Market median
+64% vs market
20202024
Net profit margin
25.1%
This company
8.1%
Market median
+210% vs market
20202024
Asset turnover
0.27×
This company
1.12×
Market median
-76% vs market
20202024
Debt / equity
3.46×
This company
0.62×
Market median
-458% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2025 | |
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Former (1) | ||
| Board of Directors | 2020 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 85% | 85% | 2024 | |
| Company | 30.21% | 30.21% | 2022 | |
| Company | 15% | 15% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
C.O.L.A. Invest As
NORDICDX AS Board members of NORDICDX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Olav Fjellså | Board of Directors | 0 companies |
| Leonard Michael Jessup | Board of Directors | 0 companies |
| Tommy Selnes | Chairman | 0 companies |
| Livar Melhus | Board of Directors | 0 companies |